Tests donor stem cells from umbilical cord tissue in children with autism
Tests donor cord-tissue stem cells in children aged 4 to 14 with autism.
Plain-language title generated from the registry record
Registry title: Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Key facts
- Where
- Amman, JordanSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 4 to 14 years who meet the criteria for autism spectrum disorder (ASD). 14 children will be enrolled.
- Age
- 4 to 14 years
- Sex
- All sexes can join.
- Disease stage
- Autism spectrum disorder (ASD).
- Earlier treatment
- Stimulant or non-stimulant medication, or medication for ADHD, must be stopped 7 days before the start. Anyone taking an SSRI must be on a stable dose for at least 30 days before entering.
Main reasons for not taking part
- Weight under 10 kg (22 lb)
- History of severe allergy
- Severe head trauma, skull fracture or stroke in the past
- Seizure within the last year, or any past or present need for seizure medication
- Premature birth before 35 weeks, or a stroke or other insult in the womb
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 14 years old?
Source: NCT06293950, who can take part
Where in Jordan
- Cell Therapy CenterAmman, JordanContact: Hanan Jafar, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Jordan
- Trial code
- NCT06293950
- Record updated
- 24 January 2025
- Original description
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.Read full original descriptionShow less
Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Inclusion: 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD.
Exclusion: Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period; Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study; Prior history of stroke in utero or other in utero insult; History of severe Allergy; History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke; Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past; Evidence or history of severe, moderate, or uncontrolled systemic disease; History of premature birth <35 weeks' gestation; Age > 14 years; Patient weighing < 10 kg; Inability to follow the prescribed dosing and follow-up schedule.